Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

Prognosis of Philadelphia-positive (Ph(+)) acute lymphoblastic leukemia (ALL) in the elderly has improved during the imatinib era. We investigated dasatinib, another potent tyrosine kinase inhibitor, in combination with low-intensity chemotherapy. Patients older than age 55 years were included in th...

সম্পূর্ণ বিবরণ

সংরক্ষণ করুন:
গ্রন্থ-পঞ্জীর বিবরন
প্রকাশিত:Blood
প্রধান লেখক: Rousselot, Philippe, Coudé, Marie Magdelaine, Gokbuget, Nicola, Gambacorti Passerini, Carlo, Hayette, Sandrine, Cayuela, Jean-Michel, Huguet, Françoise, Leguay, Thibaut, Chevallier, Patrice, Salanoubat, Celia, Bonmati, Caroline, Alexis, Magda, Hunault, Mathilde, Glaisner, Sylvie, Agape, Philippe, Berthou, Christian, Jourdan, Eric, Fernandes, José, Sutton, Laurent, Banos, Anne, Reman, Oumedaly, Lioure, Bruno, Thomas, Xavier, Ifrah, Norbert, Lafage-Pochitaloff, Marina, Bornand, Anne, Morisset, Laure, Robin, Valérie, Pfeifer, Heike, Delannoy, Andre, Ribera, Josep, Bassan, Renato, Delord, Marc, Hoelzer, Dieter, Dombret, Herve, Ottmann, Oliver G.
বিন্যাস: Artigo
ভাষা:Inglês
প্রকাশিত: American Society of Hematology 2016
বিষয়গুলি:
Clinical Trials and Observations
অনলাইন ব্যবহার করুন:https://ncbi.nlm.nih.gov/pmc/articles/PMC5085255/
https://ncbi.nlm.nih.gov/pubmed/27121472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-02-700153
ট্যাগগুলো: ট্যাগ যুক্ত করুন
কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি